Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Equity Ratio: 2018-2021

Historic Equity Ratio for Black Diamond Therapeutics (BDTX) over the last 2 years, with Sep 2021 value amounting to 0.80.

  • Black Diamond Therapeutics' Equity Ratio fell 15.47% to 0.80 in Q3 2021 from the same period last year, while for Sep 2021 it was 0.80, marking a year-over-year decrease of 15.47%. This contributed to the annual value of 0.93 for FY2020, which is 413.37% up from last year.
  • Latest data reveals that Black Diamond Therapeutics reported Equity Ratio of 0.80 as of Q3 2021, which was down 8.40% from 0.87 recorded in Q2 2021.
  • Black Diamond Therapeutics' Equity Ratio's 5-year high stood at 0.98 during Q2 2020, with a 5-year trough of -0.30 in Q4 2018.
  • Over the past 3 years, Black Diamond Therapeutics' median Equity Ratio value was 0.91 (recorded in 2021), while the average stood at 0.76.
  • In the last 5 years, Black Diamond Therapeutics' Equity Ratio skyrocketed by 413.37% in 2020 and then fell by 15.47% in 2021.
  • Black Diamond Therapeutics' Equity Ratio (Quarterly) stood at -0.30 in 2018, then climbed by 0.66% to -0.30 in 2019, then skyrocketed by 413.37% to 0.93 in 2020, then dropped by 15.47% to 0.80 in 2021.
  • Its Equity Ratio stands at 0.80 for Q3 2021, versus 0.87 for Q2 2021 and 0.90 for Q1 2021.